At eight months of follow-up, Jynneos recipients not vaccinated against smallpox had lower binding antibody concentrations than those with infection.
The test the US Centers for Disease Control and Prevention uses to identify clade I mpox cases is 'most likely not reliable' for detection of the substrain identified in the study, the authors say.
Another mpox study today showed that dose-sparing vaccine administration of the Jynneos vaccine appeared to have worked.
Receive the latest infectious disease information.
The country noted an uptick in clade 1 cases in 2023 and 2024, with 19,919 suspected cases reported.
In total, 6.4% of participants had mpox antibodies, including 4% of cis women, 7% of cis men with only cis women partners, and 8% of men who have sex with men.
The serial interval was 8.7 days in 2022 and 14.2 days in previous years.
Of 371 patients hospitalized over an 8-month period in Kamituga health zone, 88% had recently visited bars for professional sexual interactions.
Officials also urged health providers to watch for possible clade 1 cases in people with travel history or epidemiological connections to African outbreak locations.
Ten countries reported case rises in March, with the Republic of Congo reporting the largest rise in Africa.
Five studies reported 2-dose protection ranging from 66% to 90%.
Many of the problems in the mpox response were due to a deflated and exhausted public health workforce across the country.
Despite the risk of severe infection from COVID-19, the study authors found that only 40.5% of residents were up to date with COVID vaccination.
Most infections occurred at lower latitudes from January to July (not including April) but were seen mainly at higher latitudes from August to December.
